Study determines critical skills for PCPs to safely manage opioid risk in chronic pain patients

 

  • The study’s objective was to identify which skills and competencies are considered most critical for primary care providers (PCPs) to learn in order to effectively manage opioid risk in patients treated for chronic pain
  • Study participants included experts in primary care, pain management, and addiction
  • Experts in this study identified the most important skills for PCPs managing opioid risk in chronic pain patients as how to monitor opioids and how to assess for risk factors

 

Newton, MA, USA (March 16, 2012) – Primary care physicians are faced with treating a large proportion of chronic pain patients, but many do not often have specific training in the assessment and management of chronic pain, including the use of opioid medications for chronic pain management. Recognizing the significant role prescribers can play in reducing the risk of addiction, unintentional overdose, and death from the misuse and abuse of opioids, the U.S. Food and Drug Administration (FDA) has made prescriber education a central part of its Risk Evaluation and Mitigation Strategy (REMS) requirements for manufacturers of long-acting and extended-release (LA/ER) opioids.

 

With this in mind, Inflexxion’s study investigated 1) what skills and training are considered to be needed for PCPs to prescribe opioids safely and effectively to patients with chronic pain, 2) what education would physicians find most relevant to clinical practice, and 3) what would resonate with them most.

 

The full report of this study, "Identifying Primary Care Skills and Competencies in Opioid Risk Management" was published in the Fall 2011 issue of The Journal of Continuing Education in the Health Professions.

 

Inflexxion researchers interviewed a panel of 16 nationally-known experts in primary care, pain management, and addiction about the knowledge and competencies they believed were most important for treating chronic pain safely and effectively in a primary care setting. Their responses were collated and analyzed using an online concept mapping program, which offers an innovative method of summarizing and prioritizing qualitative data.

 

Results showed the impressions of what skills PCPs thought their colleagues needed most, and those that pain and addiction specialists believed PCPs should have, diverged. While both groups agreed that the most important area for education was how to manage pain patients with comorbid conditions, PCPs were more concerned that their peers learn things like understanding aberrant drug-related behavior, how to monitor compliance to therapy, and how to ensure safe and appropriate prescribing of opioids than the specialists. Specialists placed greater emphasis on PCPs learning how to formulate a treatment plan, having a general understanding of chronic pain management, and being able to teach medication safety to patients.

 

"Primary care physicians treat a high proportion of chronic pain patients but often lack training about how to assess and address issues associated with prescribing opioids when they are an appropriate component of therapy. The result may be that they could avoid treating these patients, which can lead to an under treatment of pain," says Kevin Zacharoff, MD, Vice President of Medical Affairs for Inflexxion and co-author of this study. "As pharmaceutical manufacturers and educators move forward on developing educational programs with the goal of meeting FDA concerns about the safe use of opioids, understanding the skills and competencies needed in primary care can have a tremendous positive impact on public health."

 

 

Inflexxion received funding from the National Institute of Drug Abuse (NIDA) to conduct this study.

 

 

About Inflexxion

 

Inflexxion develops scientifically-based, interactive technologies that help people improve their lives through behavioral change. Partners and customers rely on Inflexxion for online programs that reduce health-related risks, enhance clinical outcomes, and positively influence quality of care. Inflexxion has received over $64 million in grant support from the National Institutes of Health (NIH) and Small Business Innovation Research Program (SBIR), and has developed over 50 assessment, intervention and prevention programs in its behavioral health, risk management, college health, and consumer health divisions. Located in Newton, MA and founded in 1989, Inflexxion has over 90 employees.

 


 

Inflexxion, 16.03.2012 (tB).

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…
Minimalinvasive Geräte warnen ungenügend vor Unterzuckerung
Typ-1-Diabetes und Hashimoto-Thyreoiditis treten häufig gemeinsam auf

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung